Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, United Kingdom and NEW YORK, January 7, 2026 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing...
Cancer
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of...
Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026
COVINGTON, Ky., Jan. 6, 2026 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic...
St. Baldrick’s Foundation Announces 2026 Ambassadors
Los Angeles, California--(Newsfile Corp. - January 6, 2026) - The St. Baldrick's Foundation, the largest charity funder of childhood cancer...
Primefocus Health and Marshall Health Network Extend Collaboration to Support Breast Cancer Clinic
Strong Engagement and Improved Outcomes in Initial Pilot Program Demonstrate Potential for Providing Effective Remote Care for Breast CancerHUNTINGTON, W. Va....
JOURNAL OF TRANSLATIONAL MEDICINE PUBLISHES PAPER HIGHLIGHTING POTENTIAL OF THE ELEPHAS LIVE™ PLATFORM TO TRANSFORM IMMUNOTHERAPY OUTCOMES
Innovative Platform Aims to Boost Response Rates and Improve Lives of Cancer PatientsMADISON, Wis., Jan. 6, 2026 /PRNewswire/ -- Elephas...
NanOlogy Appoints John M. Goldberg, MD as Chief Medical Officer to Further its Preclinical & Clinical Large Surface Area Microparticle Investigational Drug Portfolio
FORT WORTH, Texas, Jan. 6, 2026 /PRNewswire/ -- NanOlogy, LLC, a clinical-stage oncology company, today announced the appointment of John...
Base Molecular Resonance™ Technologies (BMRT) Achieves Historic Results in U.S. Government Sponsored Test
STUART, Fla., Jan. 6, 2026 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT) today announced the successful completion of a multi-day test supporting...
Behind the Relapse No One Saw Coming: How First Ascent Biomedical Is Changing Cancer Treatment Decisions
Logan Jenner, a five-year-old battling acute myeloid leukemia, found new hope through a clinical trial that used Functional Precision Medicine...
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) observed in...
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
HOUSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with...
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) --...
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
Regulatory alignment supports rapid progress, tech transfer already underway to accelerate clinical readiness Company on track to initiate first-in-human (FIH)...
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
- Initial module submission marks an important milestone in the pre-market approval process - - Flexible modular submission framework granted...
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology...
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
January 05, 2026 Biodexa Pharmaceuticals PLC Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary...
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and...
FibroBiologics Announces Positive Preclinical Results for a Fibroblast Spheroid-derived Chondrocyte (FSdC) Spheroid Therapy for Degenerative Disc Disease
FSdC demonstrated statistically significant and superior improvement in disc preservation and structural integrity compared to other treatmentsHOUSTON, Jan. 05, 2026...
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, confirms...